Prostate-specific loss of UXT promotes cancer progression.
UXT
prostate cancer
retroelement
Journal
Oncotarget
ISSN: 1949-2553
Titre abrégé: Oncotarget
Pays: United States
ID NLM: 101532965
Informations de publication
Date de publication:
22 Jan 2019
22 Jan 2019
Historique:
received:
01
04
2018
accepted:
06
10
2018
entrez:
19
2
2019
pubmed:
19
2
2019
medline:
19
2
2019
Statut:
epublish
Résumé
Ubiquitously-expressed, prefoldin-like chaperone (UXT) also called Androgen Receptor Trapped clone-27 (ART-27) is widely expressed in human tissues. Our previous studies showed that UXT regulates transcription repression including androgen receptor (AR) signaling in prostate cancer. Here we analyzed a tissue microarray consisting of normal prostate, benign prostatic hyperplasia, high grade prostatic intraepithelial neoplasia (HGPIN) and primary prostate cancer cases for UXT protein expression. We found that HGPIN and malignant tumors have significantly decreased UXT expression compared to the normal prostate. Loss of UXT expression in primary prostate cancer is positively associated with high Gleason grade and poor relapse-free survival. We engineered prostate-specific
Identifiants
pubmed: 30774773
doi: 10.18632/oncotarget.26573
pii: 26573
pmc: PMC6366831
doi:
Types de publication
Journal Article
Langues
eng
Pagination
707-716Subventions
Organisme : NCI NIH HHS
ID : R01 CA112226
Pays : United States
Organisme : NCI NIH HHS
ID : U01 CA149556
Pays : United States
Déclaration de conflit d'intérêts
CONFLICTS OF INTEREST Authors declare no conflicts of interest.
Références
Nucleic Acids Res. 2000 Mar 15;28(6):1418-23
pubmed: 10684937
Nature. 2001 Feb 15;409(6822):860-921
pubmed: 11237011
Mol Biol Cell. 2002 Feb;13(2):670-82
pubmed: 11854421
J Mol Biol. 2002 Feb 22;316(3):459-73
pubmed: 11866511
Urol Oncol. 2004 Jul-Aug;22(4):307-12
pubmed: 15283888
Br J Cancer. 2004 Aug 31;91(5):985-94
pubmed: 15292941
J Pathol. 2006 Apr;208(5):699-707
pubmed: 16402365
Science. 1991 Dec 20;254(5039):1808-10
pubmed: 1722352
J Cell Biol. 2007 Jul 16;178(2):231-44
pubmed: 17620405
FEBS J. 2007 Aug;274(15):3960-71
pubmed: 17635584
Nature. 2007 Aug 2;448(7153):595-9
pubmed: 17671502
Curr Cancer Drug Targets. 2007 Sep;7(6):591-604
pubmed: 17896924
Oncogene. 2008 Nov 27;27(56):7106-17
pubmed: 18776922
Cancer Res. 2008 Sep 15;68(18):7541-9
pubmed: 18794142
Cancer Res. 2008 Nov 1;68(21):8954-67
pubmed: 18974140
Cancer Res. 2009 Apr 1;69(7):3140-7
pubmed: 19318562
Cancer Cell. 2010 Jul 13;18(1):11-22
pubmed: 20579941
Mob DNA. 2011 Feb 14;2(1):2
pubmed: 21320307
Mol Cell Biol. 2011 Sep;31(17):3639-52
pubmed: 21730289
Nat Struct Mol Biol. 2011 Aug 07;18(9):1006-14
pubmed: 21822284
EMBO J. 2011 Sep 20;30(19):3885-94
pubmed: 21934649
Histopathology. 2012 Jan;60(1):187-98
pubmed: 22212086
Cancer Discov. 2012 May;2(5):401-4
pubmed: 22588877
Eur Urol. 2013 May;63(5):920-6
pubmed: 22981675
PLoS Genet. 2013 Mar;9(3):e1003402
pubmed: 23555307
PLoS One. 2013 May 08;8(5):e63879
pubmed: 23667685
Proc Natl Acad Sci U S A. 2013 Sep 24;110(39):15710-5
pubmed: 24019458
J Vis Exp. 2013 Nov 02;(81):e50713
pubmed: 24300377
Redox Biol. 2014 Jan 09;2:457-65
pubmed: 24624335
Mol Cancer Res. 2014 Oct;12(10):1470-9
pubmed: 25053806
Science. 2015 Sep 18;349(6254):1351-6
pubmed: 26383955
J Biol Chem. 2016 Dec 2;291(49):25516-25528
pubmed: 27780869
J Cell Biochem. 2017 Aug;118(8):2347-2356
pubmed: 28106301
Sci Rep. 2017 Aug 1;7(1):7029
pubmed: 28765607
Genomics. 1987 Oct;1(2):113-25
pubmed: 3692483
Genes Dev. 1996 Aug 15;10(16):2067-78
pubmed: 8769649
Cell. 1996 Nov 29;87(5):905-16
pubmed: 8945517
Oncogene. 1998 Apr 2;16(13):1743-8
pubmed: 9582022